Testing KSVCBD Injection for Hard-to-Treat Autoimmune Diseases
Treatments studied
Part of Immune system & allergy clinical trials.
This early-stage trial tests a new injectable treatment called KSVCBD for autoimmune diseases that haven't responded well to standard therapies. The study aims to learn if it is safe and effective for conditions like lupus, vasculitis, and scleroderma.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 65 years old
- You have one of the listed autoimmune diseases that is either moderate-to-severe or has not responded well to previous treatments
- Your organs (heart, lungs, kidneys, liver) are functioning adequately
- You are willing to use contraception during the study if you can become pregnant
- You commit to following all study procedures and attending all appointments
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests whether a special immune cell treatment (CD19 CAR-T) can help people with certain severe autoimmune diseases that have not improved with standard therapies. It is a very early study to see if the treatment is safe and effective for conditions like lupus, systemic sclerosis, vasculitis, myositis, or Sjögren's syndrome.
This trial tests a personalized cell therapy (CAR-T cells that target CD19 and BCMA proteins) for people with lupus, Sjogren's, scleroderma, dermatomyositis, antisynthetase syndrome, immune-mediated necrotizing myopathy, rheumatoid arthritis, or ANCA-associated vasculitis that has not responded to standard treatments. The goal is to see if this therapy can reduce disease activity.
This early-stage trial tests a new injection called KSVCBD to treat neuromyelitis optica spectrum disorder (NMOSD), a rare disease where the immune system damages the optic nerve and spinal cord. The study will examine whether this treatment is safe and helps reduce relapses in patients with a specific antibody marker.
This trial tests an experimental cell therapy called KSVCBD for people with B-cell non-Hodgkin's lymphoma that has come back or not responded to standard treatments. The therapy targets two proteins (CD19 and BCMA) on cancer cells to help the immune system fight the disease.
This study tests a new injectable medicine (SG301) for people with lupus (SLE) whose current treatments are not working well enough or cause side effects. It aims to see if this targeted therapy can better control lupus symptoms.
This study tests a new investigational drug called SCTB35 for people with active systemic lupus erythematosus (SLE or lupus). It aims to see if the drug is safe and effective in controlling lupus activity when added to your current stable lupus medications.
Hear when a new Autoimmune Diseases trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.